CytoMed Therapeutics shares surge 40.02% after-hours on cell therapy advancements and strategic partnerships.

CytoMed Therapeutics surged 40.02% in after-hours trading following positive developments in its cell therapy pipeline and financial positioning. The company highlighted advancements in Natural Killer cell therapy, strategic partnerships, and a balanced leverage ratio (1.1), signaling sustainable growth and operational strength. Recent news emphasized its $10M in assets, $853,000 in annual revenues, and support from Enterprise Singapore, which bolstered investor confidence. Market reactions were driven by anticipation of innovative therapies and prudent financial management, with analysts noting the stock’s alignment with long-term industry trends. The after-hours spike reflects heightened optimism around its pipeline and strategic alliances, despite the stock’s modest revenue base.